Sandoz in the news
Generic medicines production
Tamtam found 20 recent articles about Sandoz.
- Gesamtverschuldung je Aktie von Sandoz Group Ltd – SIX:SDZ
The document discusses Sandoz Group Ltd's total debt per share on the SIX exchange.
- Switzerland - Advestra berät Sandoz bei der Platzierung von CHF 550 Millionen Anleihen
Sandoz issued CHF 550 million in dual-tranche bonds for general corporate use, advised legally by Advestra.
- Sandoz Group (SWX:SDZ) - Aktienanalyse
Sandoz Group AG develops and supplies generic medicines and biosimilars globally and faces stock undervaluation despite projected earnings growth.
- Sandoz Group AG: Aktionäre Vorstände Geschäftsführer und Unternehmensprofil | A3ETYB | CH1243598427
The document is a detailed rating and evaluation summary of Sandoz Group AG's financial, performance, and ESG metrics.
- Sandoz-Aktie: Intron Health stuft auf Verkaufen ab
Intron Health downgraded Sandoz stock to "Sell" due to concerns about overvaluation and high expectations for future growth.
- Antibiotika-Produktion: Zunehmend abhängig von Indien und China - Wirtschaft - SZ.de
Sandoz in Austria is the sole Western manufacturer of antibiotics and their active ingredients, facing pressure amid increasing reliance on India and China for production.
- Britischer Fondsmanager sieht Bewertung von SMI-Spitzenreiter äusserst kritisch
A British fund manager critically assesses Sandoz's stock valuation, suggesting a potential 50% drop without significant cash flow improvement, despite the company's "golden decade" ambitions and strong market performance.
- Sandoz Benefits From New Zealand Reliance Pathway To Rapidly Gain Paliperidone Approval
Sandoz rapidly secured approval for its generic paliperidone in New Zealand due to a new regulatory reliance pathway.
- Sandoz auf der Jefferies Global Healthcare Conference: Wachstumsstrategie Bio100 im Fokus
Sandoz presented its Bio100 strategy, aiming for accelerated growth in biosimilars and generics, increased market share, and stronger vertical integration with projected double-digit growth from 2030.
- SDZ: Biosimilar scale-up, launches and internal supply underpin the 2035 growth ambition
Sandoz plans to drive growth through biosimilar scale-up, aiming for 40-50 launches and over 30% global market share, supported by increased internal supply.
- Sandoz Group N-Aktie unter 20-Tage-Linie
Sandoz Group N-share price dropped to 89.18 EUR, crossing below its 20-day moving average, despite a long-term uptrend since September 17, 2026.
- Analysts Lift Sandoz Target, But Keep A Reduce Rating
Analysts increased Sandoz's price target to 89.9 Swiss francs after an upgraded 2026 guidance, but kept a 'Reduce' rating due to the stock's substantial post-listing rally.
- Sandoz stock: Enzeevu launch adds a US commercial channel
Sandoz launched Enzeevu, a biosimilar for retinal diseases, in the US and signed a private-label agreement for its commercialization.
- Sandoz-Aktie: Enzeevu startet in den USA, Vertrag folgt
Sandoz launched its biosimilar Enzeevu in the US for retinal diseases and secured a private label contract for its distribution.
- AlphaValue/Baader Europe hebt Kursziel für Sandoz nach aktualisierter Prognose für 2026 an
AlphaValue/Baader Europe increased Sandoz's price target after revising its 2026 forecast, with the document detailing various investment rating methodologies.
- Sandoz launches Eylea biosimilar Enzeevu in USA
Sandoz introduced Enzeevu, a biosimilar of Eylea, in the USA for various ophthalmic conditions and secured a second sales channel.
- Sandoz-Aktie: Augenmittel Enzeevu startet in den USA – Private-Label-Deal ab 2027
Sandoz launched its Eylea biosimilar Enzeevu in the US market, securing a multi-year private label agreement.
- Sandoz Group AG (SDZ) Launches Enzeevu in US, Adds Private-Label Channel
Sandoz launched the biosimilar Enzeevu in the US market and entered a private-label agreement for its commercialization.
- Sandoz startet US-Vertrieb des Medikaments Enzeevu gegen Netzhauterkrankungen
Sandoz has started the US distribution of Enzeevu, a drug for retinal diseases, while the document also details various company rating methodologies.
- Sandoz launches Enzeevu biosimilar for retinal diseases in US
Sandoz launched Enzeevu, a biosimilar for retinal diseases, in the US market, interchangeable with Eylea.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Sandoz?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies